medigraphic.com
ISSN 2683-1678 (Print)
Órgano Oficial de la Sociedad
Latinoamericana de lnfectología Pediátrica.
Órgano de la Asociación Mexicana de
Infectología Pediátrica, A.C.
Órgano difusor de la Sociedad Española
de lnfectología

2017, Number 1

Next >>

Rev Latin Infect Pediatr 2017; 30 (1)

First dengue vaccine

Arredondo GJL

Language: Spanish
References: 13
Page: 4-5
PDF size: 144.55 Kb.


Text Extraction

No abstract.


REFERENCES

  1. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL et al. The global distribution and burden of dengue. Nature. 2013; 496 (7446): 504-507.

  2. Capeding MR, Tran NH, Hadinegoro SR, Ismail HI, Chotpitayasunondh T, Chua MN et al. Clinical effi cacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet. 2014; 384 (9951): 1358-1365.

  3. Villar L, Dayan GH, Arredondo-García JL, Rivera DM, Cunha R, Deseda C et al. Effi cacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med. 2015; 372 (2): 113-123.

  4. Strategic Advisory Group of Experts (SAGE) on inmunization. Available in: http://www.who.int/immunization/policy/sage/ en/. Accessed 22 July 2016.

  5. SAGE Working Group on Dengue Vaccines and Vaccination. Available in: http://www.who.int/immunization/policy/sage/ sage_wg_dengue_mar2015/en/. Accessed 7 October 2015.

  6. SAGE Working Group on Dengue Vaccines and Vaccination. Available in: http://www.who.int/immunization/sage/ meetings/2016/april/en/. Accessed 21 January 2017.

  7. Hadinegoro SR, Arredondo-García JL, Capeding MR, Deseda C, Chotpitayasunondh T, Dietze R et al. Effi cacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med. 2015; 373 (13): 1195-1206.

  8. Worlg Health Organization. WHO background paper, http:// www.who.int/entity/immunizatin/sage/meetings/2016/april/1_ Background_Paper_Dengue_Vaccines_2016_03_17. pdf?ua=1. Accessed 22 July 2016.

  9. Safety of CYD-TDV dengue vaccine. Weekly Epidemiological Record. 2015; 90 (34): 421-432.

  10. Wilder-Smith A, Gubler DJ. Dengue vaccines at a crossroad. Science. 2015; 350 (6261): 626-627.

  11. Gessner BD, Feikin DR. Vaccine preventable disease incidence as a complement to vaccine effi cacy for setting vaccine policy. Vaccine. 2014; 32 (26): 3133-3138.

  12. Gessner BD, Wilder-Smith A. Estimating the public health importance of the CYD-tetravalent dengue vaccine: Vaccine preventable disease incidence and numbers needed to vaccinate. Vaccine. 2016; 34 (20): 2397-2401.

  13. Saadatian-Elahi M, Horstick O, Breiman RF, Gessner BD, Gubler DJ, Louis J et al. Beyond efficacy: the full public health impact of vaccines. Vaccine. 2016; 34 (9): 1139- 1147.




2020     |     www.medigraphic.com